Antera Therapeutics, a Boston, MA-based developer of a physician-recommended regimen for the early introduction of peanuts, raised $1.7m in seed funding.
The round was led by RA Capital Management with participation from Joe Gentile, CEO of Stemgent, Martin Madaus, former President, Chairman and CEO of Millipore, and Gil Omenn, CEO of University of Michigan Health System.
The company will use the funds to accelerate the national launch of AralyteTM.
Led by Clarence Friedman, founder and CEO, Antera offers Aralyte, a doctor-recommended method of early peanut introduction into infants’ diets. Each single-use vial contains the precise peanut protein amounts advised by clinical research in a liquid formula that is easy for infants to consume. The first dose of Aralyte – currently available for pre-order – can be administered with a physician to ensure safety and reduce parental anxiety.